

1. (Navani, N., et al., Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. *Lancet Respir Med*, 2015. 3(4): p. 282-9)
2. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Flentje M, Huber RM, Engel-Riedel W, **Andreas S**, Kollmeier J, Staar S, Dickgreber N, Vaissiere N, De Almeida C, Edlich B, Fietkau R. *Strahlenther Onkol*. 2016 Apr;192(4):216-22. doi: 10.1007/s00066-016-0941-8. Epub 2016 Jan 25.
3. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han JY, Hida T, Moro-Sibilot D, Conkling P, Gandara DR, **Rittmeyer A**, Gandhi M, Yu W, Matheny C, Patel H, Sandler A, Ballinger M, Kowanetz M, Park K. *Eur J Cancer*. 2018 Dec 15;107:124-132. doi: 10.1016/j.ejca.2018.11.020. [Epub ahead of print]
4. Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Ponce Aix S, **Rittmeyer A**, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L. *J Thorac Oncol*. 2018 Dec;13(12):1906-1918. doi: 10.1016/j.jtho.2018.08.2027. Epub 2018 Sep 11.
5. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, **Rittmeyer A**, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE. *Clin Cancer Res*. 2018 Sep 11. doi: 10.1158/1078-0432.CCR-18-1590.
6. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, **Rittmeyer A**, Fehrenbacher L, Otto G, Malboeuf C, Lieber DS, Lipson D, Siltrerra J, Amler L, Riehl T, Cummings CA, Hegde PS, Sandler A, Ballinger M, Fabrizio D, Mok T, Shames DS. *Nat Med*. 2018 Sep;24(9):1441-1448. doi: 10.1038/s41591-018-0134-3. Epub 2018 Aug 6.
7. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer. Bordoni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M, Sandler A, Yu W, He P, Matheny C, Felizzi F, **Rittmeyer A**. *Clin Lung Cancer*. 2018 Sep;19(5):441-449.e4. doi: 10.1016/j.clcc.2018.05.011. Epub 2018 May 31.
8. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. Fehrenbacher L, von Pawel J, Park K, **Rittmeyer A**, Gandara DR, Ponce Aix S, Han JY, Gadgeel SM, Hida T, Cortinovis DL, Cobo M, Kowalski DM, De Marinis F, Gandhi M, Danner B, Matheny C, Kowanetz M, He P, Felizzi F, Patel H, Sandler A, Ballinger M, Barlesi F. *J Thorac Oncol*. 2018 Aug;13(8):1156-1170. doi: 10.1016/j.jtho.2018.04.039. Epub 2018 May 17.
9. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. Claret L, Jin JY, Ferté C, Winter H, Girish S, Stroh M, He P, Ballinger M, Sandler A, Joshi A, **Rittmeyer A**, Gandara D, Soria JC, Bruno R. *Clin Cancer Res*. 2018 Jul 15;24(14):3292-3298. doi: 10.1158/1078-0432.CCR-17-3662. Epub 2018 Apr 23.
10. Metronomic treatment of advanced non-small cell lung cancer with daily oral vinorelbine a phase-I trial Guetz S, Tufman A, von Pawel J, **Rittmeyer A**, Borgmeier A, Ferré P, Edlich B, Huber RM. *Onco Targets Ther*. 2017 Feb 21;10:1081-1089. doi: 10.2147/OTT.S122106.
11. Prospects and progress of atezolizumab in non-small cell lung cancer Vansteenkiste J, Wauters E, Park K, **Rittmeyer A**, Sandler A, Spira A. *Expert Opin Biol Ther*. 2017 Jun;17(6):781-789. doi: 10.1080/14712598.2017.1309389. Epub 2017 Mar 28.
12. Chemotherapy in the Elderly with Non-Small Cell Lung Cancer: A Non-Interventional, Prospective, Multicentric Observational Study Heigener DF, Hoeffken G, Wuerflein D, Feurer M, **Rittmeyer A**, Huber RM, Pietsch M, Ring A, Deppermann KM. *Dtsch Med Wochenschr*. 2017 Feb;142(4):e21-e27. doi: 10.1055/s-0042-121785. Epub 2017 Feb 24.

13. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. **A Rittmeyer**, F Barlesi, D Waterkamp, K Park, F Ciardiello, JvPawel, SM Gadgeel, T Hida, DM Kowalski, M Cobo Dols, DL Cortinovis, J Leach, J Polikoff, C Barrios, F Kabbinavar, O Arén Frontera, F De Marinis, H Turna, JS Lee, M Ballinger, M Kowanetz, P He, DS Chen, A Sandler, DR Gandara. *The Lancet* 2017; 389: 255–65
14. Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study. Pujol JL, De Pas T, **Rittmeyer A**, Vallières E, Kubisa B, Levchenko E, Wiesemann S, Masters GA, Shen R, Tjulandin SA, Hofmann HS, Vanhoutte N, Salaun B, Debois M, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF. *J Thorac Oncol*. 2016 Aug 17. pii: S1556-0864(16)30835-8. doi: 10.1016/j.jtho.2016.08.120.
15. Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer. Hirsch FR, Govindan R, Zvirbule Z, Braiteh F, **Rittmeyer A**, Belda-Iniesta C, Isla D, Cosgriff T, Boyer M, Ueda M, Phan S, Gandara DR. *Clin Lung Cancer*. 2016 Jun 4. pii: S1525-7304(16)30116-4. doi: 10.1016/j.clcc.2016.05.011. [
16. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, **Rittmeyer A**; POPLAR Study Group. *Lancet*. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0.
17. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, **Rittmeyer A**. *Ann Oncol*. 2014 May;25(5):1044-52. doi: 10.1093/annonc/mdu098.
18. Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). **Rittmeyer A**, Gorbunova V, Vikström A, Scherpereel A, Kim JH, Ahn MJ, Chella A, Chouaid C, Campbell AK, Barlesi F. *J Thorac Oncol*. 2013 Nov;8(11):1409-16. doi: 10.1097/JTO.0b013e3182a46bcf.
19. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). Barlesi F, Scherpereel A, **Rittmeyer A**, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. *J Clin Oncol*. 2013 Aug 20;31(24):3004-11. doi: 10.1200/JCO.2012.42.3749.
20. Multidisciplinary treatment of lung cancer in older patients: A review. Radovic M, Kanavaran R, **Rittmeyer A**, Früh M, Minervini F, Glatzer M, Putora PM. *J Geriatr Oncol*. 2018 Oct 3. pii: S1879-4068(18)30198-X. doi: 10.1016/j.jgo.2018.09.005. [Epub ahead of print]
21. Smoking, chronic obstructive pulmonary disease and lung cancer **Andreas S**, Herth FJ, **Rittmeyer A**, Kyriss T, Raupach T. *Pneumologie*. 2007 Sep;61(9):590-4.
22. Treatment of limited disease small cell lung cancer: the multidisciplinary team Glatzer M, **Rittmeyer A**, Müller J, Opitz I, Papachristofilou A, Psallidas I, Früh M, Born D, Putora PM. *Eur Respir J*. 2017 Aug 24;50(2). pii: 1700422. doi: 10.1183/13993003.00422-2017.
23. Smoking cessation in lung cancer-achievable and effective **Andreas S\***, **Rittmeyer A\***, **Hinterthaler M**, Huber RM. *Dtsch Arztebl Int*. 2013 Oct;110(43):719-24. doi: 10.3238/arztebl.2013.0719.
24. Quality of Life in Patients with NSCLC Receiving Maintenance Therapy. **Rittmeyer A**. *Cancers (Basel)*. 2015 May 29;7(2):950-62. doi: 10.3390/cancers7020817